On Tuesday, Yum! Brands, Inc. (NYSE:YUM)’s shares inclined 0.54% to $90.07.
Yum! Brands, Inc. (YUM) still has plenty of growth potential in China.
The Louisville-based restaurant company, which comprises KFC Corp., Taco Bell Corp. and Pizza Hut Inc., has hailed itself as the industry leader in China. KFC has twice as many stores in China as McDonald’s Corp., according to a presentation at Yum Brands’ (NYSE: YUM) 2015 China Investors Conference this weekend.
Despite this, the company has only five stores per million people in China, contrast with 57 restaurants per million residents in the United States, the presentation states.
YUM Brands has focused its growth on cities, and about 15 million Chinese people migrate to cities each year. The Chinese urban population is expect to grow by 60 percent by 2020.
To stay competitive, Yum Brands is revamping its menus in China. With KFC in particular, the company has emphasized health and is focused on fewer, but stronger menu items.
YUM! Brands, Inc., together with its auxiliaries, operates quick service restaurants. It operates in five segments: YUM China, YUM India, the KFC Division, the Pizza Hut Division, and the Taco Bell Division. The company develops, operates, franchises, and licenses a system of restaurants, which prepare, package, and sell various food items. As of February 4, 2015, it operated about 41,000 restaurants in about 120 countries and territories primarily under the KFC, Pizza Hut, and Taco Bell brands, which specialize in chicken, pizza, and Mexican-style food categories.
Williams Partners LP (NYSE:WPZ)’s shares dropped -1.22% to $48.43.
Williams and The Conservation Fund declared 17 conservation projects which will receive more than $2.5 million in funding through the Atlantic Sunrise Environmental Stewardship Program. Together, these projects will restore over 10 miles of wildlife habitat along streams, prevent thousands of pounds of harmful nutrients from entering waterways, and support the construction of eight miles of new trails in central and southeastern Pennsylvania.
Williams Partners L.P., an energy infrastructure company, focuses on connecting North Americas hydrocarbon resource plays to growing markets for natural gas and natural gas liquids (NGL). It operates in Northeast G&P, Atlantic-Gulf, West, and NGL & Petchem Services segments. The Northeast G&P segment comprises midstream gathering and processing businesses in the Marcellus and Utica shale regions; and a 51 percent equity investment in Laurel Mountain Midstream, LLC, in addition to a 47.5 percent equity investment in Caiman Energy II, LLC.
At the end of Tuesday’s trade, ARM Holdings plc (ADR) (NASDAQ:ARMH)‘s shares surged 0.47% to $49.27.
ARM Holdings plc (ADR) (ARMH) has signed an expansive long-term graphics technology agreement with Samsung to enable the creation of next generation devices capable of delivering even more compelling visual experiences. The subscription license covers ARM® Mali™ graphics processing units (GPUs) counting the Mali-T820/830/860, the recently declared Mali-T880 and all future Mali GPUs.
This long term contract with ARM allows Samsung to continue creating innovative products addressing a range of price and performance points to meet the evolving needs of multiple markets. Samsung is already utilizing ARM Mali technology in SoCs powering an impressive range of leading consumer products.
ARM Holdings plc, together with its auxiliaries, designs microprocessors, physical intellectual property (IP), and related technology and software. The company also sells development tools that enhance the performance of embedded applications. Its products comprise microprocessor cores that comprise of specific functions, such as video, graphics, and display technology IP; and physical IP components for the design and manufacture of integrated circuits, which comprise embedded memory, standard cell, and input/output components.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), ended its Tuesday’s trading session with 3.54% gain, and closed at $14.93.
BioCryst Pharmaceuticals, Inc. (BCRX) and CSL Limited (ASX:CSL) (CSLLY) — BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, declared recently that it has licensed RAPIVAB (peramivir injection) for the treatment of influenza to CSL Limited, a global biopharmaceutical company.
RAPIVAB is an intravenous (I.V.) treatment indicated in the U.S. for acute uncomplicated influenza in adults 18 years and older. It is also presently licensed for use in Japan and Korea, and is the first and only approved intravenous influenza treatment in the world.
RAPIVAB will be commercialized by CSL’s partner, bioCSL, which specializes in influenza prevention through the supply of seasonal and pandemic influenza vaccine to global markets.
Under the terms of the agreement, bioCSL obtains worldwide rights to commercialize RAPIVAB, with the exception of Japan, Korea, Taiwan and Israel. BioCryst retains all rights to pursue pandemic stockpiling orders for RAPIVAB from the U.S. government, while bioCSL is responsible for government stockpiling outside the U.S.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates comprise peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
